BioLineRx announced on the release date it entered an agreement to sell 14.4% of future APHEXDA royalties to Soleus Capital for $5.6 million. [1]
Congress stated that the Indian government is not concerned with national economic health, but instead focused on Rahul Gandhi speaking about economic issues. [2] BioLineRx CEO Philip Serlin stated proceeds will be used to advance the GLIX1 Phase 1/2a clinical trial. [3] BioLineRx retains all rights to commercial milestone payments under the existing Ayrmid Pharma license agreement. [4]
Rahul Gandhi asserted India has a broken manufacturing base and deep structural problems in its education system. [5] Rahul Gandhi stated that India is facing an 'economic disaster' characterized by massive unemployment. [6] Completion of the partial loan repayment will eliminate BioLineRx's $4 million minimum cash balance requirement. [7]
This news report was last updated by PTI on 18 November 2026 at 15:12 IST. [8]BioLineRx anunció en la fecha del comunicado que celebró un acuerdo para vender el 14.4% de las regalías futuras de APHEXDA a Soleus Capital por $5.6 millones. [1]
El Congreso afirmó que el gobierno de la India no se preocupa por la salud económica nacional, sino que se centra en que Rahul Gandhi se exprese sobre temas económicos. [2] El director general de BioLineRx, Philip Serlin, declaró que los fondos obtenidos se utilizarán para avanzar en el ensayo clínico de Fase 1/2a de GLIX1. [3] BioLineRx conserva todos los derechos sobre los pagos por hitos comerciales establecidos en el acuerdo de licencia vigente con Ayrmid Pharma. [4]
Rahul Gandhi afirmó que la India cuenta con una base manufacturera deteriorada y graves problemas estructurales en su sistema educativo. [5] Rahul Gandhi indicó que la India enfrenta un «desastre económico» caracterizado por un desempleo masivo. [6] La finalización del pago parcial del préstamo eliminará el requisito de saldo mínimo de efectivo de $4 millones que aplica a BioLineRx. [7]
Este informe noticioso fue actualizado por última vez por PTI el 18 November 2026 a las 15:12 IST. [8]
Proof8 sources · 2 publishers · signed
What this stands on
BioLineRx announced on the release date it entered an agreement to sell 14.4% of future APHEXDA royalties to Soleus Capital for $5.6 million. · Cision PR Newswire
Congress stated that the Indian government is not concerned with national economic health, but instead focused on Rahul Gandhi speaking about economic issues. · Deccan HeraldIndia
BioLineRx CEO Philip Serlin stated proceeds will be used to advance the GLIX1 Phase 1/2a clinical trial. · Cision PR Newswire
BioLineRx retains all rights to commercial milestone payments under the existing Ayrmid Pharma license agreement. · Cision PR Newswire
Rahul Gandhi asserted India has a broken manufacturing base and deep structural problems in its education system. · Deccan HeraldIndia
Rahul Gandhi stated that India is facing an 'economic disaster' characterized by massive unemployment. · Deccan HeraldIndia
Completion of the partial loan repayment will eliminate BioLineRx's $4 million minimum cash balance requirement. · Cision PR Newswire
This news report was last updated by PTI on 18 November 2026 at 15:12 IST. · Deccan HeraldIndia
1 of the 2 publishers publishes from India. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · signed receipt ✓ · 8 sources · v 001The worldThe recordThe writingThe filing
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, November 18, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
1 of the 2 publishers publishes from India. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.